98%
921
2 minutes
20
Objective: To identify risk factors for bleeding and thrombotic complications during extracorporeal membrane oxygenation (ECMO) support in adults and to develop a predictive model based on these factors.
Method: Data from 323 adult patients treated with ECMO in the Medical Information Mart for Intensive Care IV (MIMIC-IV) database were retrospectively analyzed. Demographic information, clinical characteristics, and laboratory test results were collected. Kaplan-Meier (K-M) and Cox regression analyses were used to identify risk factors for bleeding and thrombotic complications and construct a predictive model.
Results: Bleeding and thrombotic complications was noted in 84 (26.0%) patients, with a median onset time of 13 days after ECMO. Univariate analysis identified age, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, ECMO indication, ECMO withdrawal, extracorporeal cardiopulmonary resuscitation (ECPR), and coagulation function as potential risk factors (all P < 0.05). Multivariate analysis revealed that ECMO withdrawal and platelet count (PLT) were independent protective factors, while D-dimer was an independent risk factor (P < 0.05). A predictive model was developed based on ECMO withdrawal, D-dimer, and PLT, with areas under the curves (AUCs) of 0.932, 0.931, and 0.941 for predicting bleeding complications at 6, 9, and 12 days after ECMO treatment, respectively.
Conclusion: The incidence of ECMO-related bleeding and thrombotic complications is high. ECMO withdrawal, PLT, and D-dimer are independent influencing factors. This predictive model can assist in early identification of high-risk patients and guide clinical decision-making.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261148 | PMC |
http://dx.doi.org/10.62347/AKFK5120 | DOI Listing |
Case Rep Hematol
August 2025
Central Diagnostic Laboratories, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Factor XIII (FXIII) deficiency is a rare coagulopathy with an estimated prevalence of approximately 1 in 1 to 2 million, affecting males and females with equal frequency. FXIII plays a critical role in hemostasis by stabilizing fibrin clots through covalent cross-linking of fibrin monomers, thereby conferring mechanical resistance and durability to the clot structure. Clinically, FXIII deficiency presents with a spectrum of hemorrhagic manifestations including bleeding from the umbilical cord, intracranial hemorrhage, recurrent miscarriages, menorrhagia, epistaxis, gingival bleeding, and poor wound healing.
View Article and Find Full Text PDFCureus
August 2025
Department of Neurology, National Hospital Organization Disaster Medical Center, Tokyo, JPN.
Bacterial meningitis and infectious cavernous sinus thrombosis (CST) are both life-threatening central nervous system infections, often caused by sinusitis. While cerebrovascular complications are well-recognized in bacterial meningitis, their association with CST is rare. A 69-year-old man presented with a 19-day history of headache, followed by diplopia.
View Article and Find Full Text PDFCureus
August 2025
Department of Anaesthesiology, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, ISR.
Pregnancy in women with Ehlers-Danlos syndrome (EDS) carries elevated risks, including prematurity, hemorrhage, and maternal morbidity, posing significant anesthetic challenges. We present the case of a 36-year-old woman with classical EDS (cEDS) and multiple comorbidities, including postural orthostatic tachycardia syndrome, bronchial asthma, congenital adrenal hypoplasia, and chronic venous thrombosis, who underwent an elective cesarean section. A multidisciplinary team developed a comprehensive perioperative plan featuring ultrasound-guided spinal anesthesia, extended post-anesthesia observation, and coordinated recommendations from cardiology, hematology, endocrinology, pulmonology, and other specialties.
View Article and Find Full Text PDFBlood Vessel Thromb Hemost
August 2025
Hematology, Thrombosis and Hemostasis Research Program, Versiti Blood Research Institute, Wauwatosa, WI.
Unopposed platelet activation can be associated with pathologic thrombosis. An intact growth arrest-specific gene 6 (GAS6)/Mer receptor tyrosine kinase (MERTK) signaling pathway contributes importantly to potentiating platelet activation triggered by molecular agonists ex vivo and thrombus stabilization in vivo. We describe, herein, the inhibition of platelet function and stable thrombus formation conferred by iMer, a naturally occurring MERTK splice variant, that acts as a GAS6 decoy receptor and decreases phosphorylation of MERTK.
View Article and Find Full Text PDFBlood Vessel Thromb Hemost
August 2025
Divsion of Hematology, Oncology & Bone Marrow Transplantation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, MO.
Clotting factor concentrate (CFC), used to treat and prevent bleeding in hemophilia, is rendered ineffective if clotting factor neutralizing antibodies (inhibitors) develop. Inhibitors occur most often in children, early in treatment. The American Thrombosis and Hemostasis Network (ATHN) 8: US Cohort Study of Previously Untreated Patients (PUPs) with Congenital Hemophilia, conducted in children born in 2010 to 2020 with severe or moderate hemophilia, was designed to determine the percentage of participants who developed a confirmed, clinically significant inhibitor within the first 50 CFC exposure days (EDs).
View Article and Find Full Text PDF